191 related articles for article (PubMed ID: 23994016)
1. Water-mediated solid-state transformation of a polymorphic drug during aqueous-based drug-layer coating of pellets.
Lust A; Lakio S; Vintsevits J; Kozlova J; Veski P; Heinämäki J; Kogermann K
Int J Pharm; 2013 Nov; 456(1):41-8. PubMed ID: 23994016
[TBL] [Abstract][Full Text] [Related]
2. Hydroxypropyl methylcellulose microspheres with piroxicam and piroxicam-hydroxypropyl-beta-cyclodextrin inclusion complex.
Jug M; Bećirević-Laćan M; Cetina-Cizmek B; Horvat M
Pharmazie; 2004 Sep; 59(9):686-91. PubMed ID: 15497750
[TBL] [Abstract][Full Text] [Related]
3. Electrospun nanofibers as a potential controlled-release solid dispersion system for poorly water-soluble drugs.
Paaver U; Heinämäki J; Laidmäe I; Lust A; Kozlova J; Sillaste E; Kirsimäe K; Veski P; Kogermann K
Int J Pharm; 2015 Feb; 479(1):252-60. PubMed ID: 25549852
[TBL] [Abstract][Full Text] [Related]
4. Polymorphic form of piroxicam influences the performance of amorphous material prepared by ball-milling.
Naelapää K; Boetker JP; Veski P; Rantanen J; Rades T; Kogermann K
Int J Pharm; 2012 Jun; 429(1-2):69-77. PubMed ID: 22433471
[TBL] [Abstract][Full Text] [Related]
5. Solid-state dependent dissolution and oral bioavailability of piroxicam in rats.
Lust A; Laidmäe I; Palo M; Meos A; Aaltonen J; Veski P; Heinämäki J; Kogermann K
Eur J Pharm Sci; 2013 Jan; 48(1-2):47-54. PubMed ID: 23085546
[TBL] [Abstract][Full Text] [Related]
6. Influence of cyclodextrin complexation on piroxicam gel formulations.
Jug M; Bećirević-Laćan M; Kwokal A; Cetina-Cizmek B
Acta Pharm; 2005 Sep; 55(3):223-36. PubMed ID: 16375834
[TBL] [Abstract][Full Text] [Related]
7. Insight into the solubility and dissolution behavior of piroxicam anhydrate and monohydrate forms.
Paaver U; Lust A; Mirza S; Rantanen J; Veski P; Heinämäki J; Kogermann K
Int J Pharm; 2012 Jul; 431(1-2):111-9. PubMed ID: 22554403
[TBL] [Abstract][Full Text] [Related]
8. Piroxicam/2-hydroxypropyl-beta-cyclodextrin inclusion complex prepared by a new fluid-bed coating technique.
Zhang X; Wu D; Lai J; Lu Y; Yin Z; Wu W
J Pharm Sci; 2009 Feb; 98(2):665-75. PubMed ID: 18543294
[TBL] [Abstract][Full Text] [Related]
9. X-ray powder diffractometry in combination with principal component analysis--a tool for monitoring solid state changes.
Kogermann K; Veski P; Rantanen J; Naelapää K
Eur J Pharm Sci; 2011 Jul; 43(4):278-89. PubMed ID: 21575718
[TBL] [Abstract][Full Text] [Related]
10. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
[TBL] [Abstract][Full Text] [Related]
11. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
Maghsoodi M; Sadeghpoor F
Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
[TBL] [Abstract][Full Text] [Related]
12. Effect of drug-polymer interactions on the aqueous solubility of milled solid dispersions.
Al-Obaidi H; Lawrence MJ; Shah S; Moghul H; Al-Saden N; Bari F
Int J Pharm; 2013 Mar; 446(1-2):100-5. PubMed ID: 23410988
[TBL] [Abstract][Full Text] [Related]
13. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets.
Lai F; Pini E; Angioni G; Manca ML; Perricci J; Sinico C; Fadda AM
Eur J Pharm Biopharm; 2011 Nov; 79(3):552-8. PubMed ID: 21820052
[TBL] [Abstract][Full Text] [Related]
14. Towards improved solubility of poorly water-soluble drugs: cryogenic co-grinding of piroxicam with carrier polymers.
Penkina A; Semjonov K; Hakola M; Vuorinen S; Repo T; Yliruusi J; Aruväli J; Kogermann K; Veski P; Heinämäki J
Drug Dev Ind Pharm; 2016; 42(3):378-88. PubMed ID: 26065533
[TBL] [Abstract][Full Text] [Related]
15. A novel white film for pharmaceutical coating formed by interaction of calcium lactate pentahydrate with hydroxypropyl methylcellulose.
Sakata Y; Shiraishi S; Otsuka M
Int J Pharm; 2006 Jul; 317(2):120-6. PubMed ID: 16621357
[TBL] [Abstract][Full Text] [Related]
16. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.
Yan YD; Sung JH; Kim KK; Kim DW; Kim JO; Lee BJ; Yong CS; Choi HG
Int J Pharm; 2012 Jan; 422(1-2):202-10. PubMed ID: 22085435
[TBL] [Abstract][Full Text] [Related]
17. Effect of glucosamine HCl on dissolution and solid state behaviours of piroxicam upon milling.
Al-Hamidi H; Edwards AA; Douroumis D; Asare-Addo K; Nayebi AM; Reyhani-Rad S; Mahmoudi J; Nokhodchi A
Colloids Surf B Biointerfaces; 2013 Mar; 103():189-99. PubMed ID: 23201737
[TBL] [Abstract][Full Text] [Related]
18. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
Zahedi P; Lee PI
Eur J Pharm Biopharm; 2007 Mar; 65(3):320-8. PubMed ID: 17182231
[TBL] [Abstract][Full Text] [Related]
19. Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique.
Cao QR; Liu Y; Xu WJ; Lee BJ; Yang M; Cui JH
Int J Pharm; 2012 Sep; 434(1-2):325-33. PubMed ID: 22688251
[TBL] [Abstract][Full Text] [Related]
20. Dissolution testing of amorphous solid dispersions.
Kogermann K; Penkina A; Predbannikova K; Jeeger K; Veski P; Rantanen J; Naelapää K
Int J Pharm; 2013 Feb; 444(1-2):40-6. PubMed ID: 23370435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
